Keynote Speakers
Peter H. Seeberger
Max Planck Institute of Colloids and Iterfaces, Potsdam, Germany
Freie Universität, Berlin, Germany
Synthetic glycans as basis for vaccines, therapeutic antibodies and diagnostics
Stephan Bachmann
F. Hoffmann-La Roche Ltd.,
Basel, Switzerland
Catalysis as key technology for the synthesis and scale-up of APIs and their intermediates
Frank Wagner
Charité, Berlin, Germany
Focus on early clinical trials
Invited Speakers
Graciela Andrei
Rega Institute for Medical Research, KU Leuven, Belgium
Herpesvirus drug-resistance: challenges and opportunities
Daniela Angst
Novartis, Basel, Switzerland
Remibrutinib, a covalent BTK inhibitor with best-in-class selectivity: discovery and clinical results
Martina Benešová-Schäfer
German Cancer Research Center, Heidelberg, Germany
Pharmaceutical radiochemistry in modern nuclear medicine
Andrea Brancale
UCT Prague, Czech Republic
Kick-start new drug design projects using computer-aided drug design
Oliviana Calin-Eller
E. Blum & Co. AG, Zurich, Switzerland
Patents: Why? What? How?
Richard Clarkson
Cardiff University, UK
Targeting cells responsible for metastatic disease
Camille Correia
Merck Electronics KGaA, Darmstadt, Germany
Modular continuous automation for laboratories and production
Deborah Fass
Weizmann Institute of Science, Rehovot, Israel
Structures of mucin glycoproteins inspire molecular methods for modulating mucosal functions
Paulina Kaplonek
Moderna, USA
Identifying the correlates of immunity for better vaccine design
Valery Khrizanovsky
Weizmann Institute of Science, Rehovot, Israel
Senescent cells in aging and age-related disease: the good, the bad and the ugly
Jan Konvalinka
IOCB Prague, Czech Republic
Chemical-biology tools in drug development
Sima Lev
Weizmann Institute of Science, Rehovot, Israel
Triple-negative breast cancer: heterogeneity and targeted therapy
David Margulies
Weizmann Institute of Science, Rehovot, Israel
Detecting proteins and protein-inhibitor interactions with ‘turn-on’ fluorescent molecular probes: design principles and applications in medical diagnosis, cell imaging and drug Discovery
Henry Maun
Genentech, South San Francisco, USA
From bench to bedside: Understanding mechanisms of inhibitory anti-tryptase antibodies for the treatment of asthma
Petra Ménová
UCT Prague, Czech Republic
How are new drugs born?
Jitka Palich Fučíková
Sotio Biotech Department of Immunology, 2nd Medical school, Charles University
The role of immune system in cancer therapy
Christoph Rademacher
University of Vienna, Austria
Cell-specific targeted delivery of therapeutics
Pavlína Řezáčová
IOCB Prague, Czech Republic
Structure-assisted design of enzyme inhibitors
Jitka Riedl
Bicycle Therapeutics, Cambridge, UK
Attacking from all angles: EphA2 targeting Bicycle® peptides for precision guided cancer therapy via multiple approaches
Menachem Rubinstein
Weizmann Institute of Science, Rehovot, Israel
Directing viral vectors to specific cell types for oncolytic virotherapy and in vivo gene therapy
Gideon Schreiber
Weizmann Institute of Science, Rehovot, Israel
Reversing protonation of weakly basic drugs greatly enhances intracellular diffusion and decreases lysosomal sequestration
Jan Skácel
IOCB Prague, Czech Republic
A postgraduate student’s perspective on drug discovery in academia: Development of PNP inhibitors
Marek Šťastný
Medical Department, Bristol-Myers Squibb
Cancer immunotherapies based on anti-PD1: clinical perspectives and challenges
Kvido Stříšovský
IOCB Prague, Czech Republic
The elusive mechanisms of unexpected regulators of inflammatory and growth factor signalling
Igor Ulitsky
Weizmann Institute of Science, Rehovot, Israel
Therapeutic targeting of RNA molecules
Kateřina Vávrová
Faculty of Pharmacy Hradec Kralove, Charles University, Czech Republic
Ceramides in the skin: extraordinary lipids for an extraordinary barrier
Milan Vrábel
IOCB Prague, Czech Republic
Chemical engineering of cell surfaces for cancer immunotherapy
Stella Vukelic
AbbVie, Ludwigshafen, Germany
Molecular obesity – An addiction in drug discovery?
Yosef Yarden
Weizmann Institute of Science, Rehovot, Israel
Overcoming resistance of lung cancer to tyrosine kinase inhibitors
